FDA Approves Pandemic Flu Vaccine From SEQIRUS/CSL Behring

Medscape  reports that the FDA has approved Audenz, “the first and only adjuvanted, cell-based pandemic vaccine to provide active immunization against the influenza A virus H5N1 strain.” According to Medscape, “Influenza A (H5N1) monovalent vaccine, adjuvanted...is for use in individuals aged 6 months and older.” The vaccine is “designed to be rapidly deployed to help protect the US population and can be stockpiled for first responders in the event of a pandemic.”

  

Healio also covers the story.

Leading pharmaceutical companies and total global vaccine market share 2017 and 2024

The top ten pharmaceutical companies based on global vaccine revenue market share in 2017 and a projection for 2024 include companies like CSL Behring.

In 2017, GlaxoSmithKline (GSK) was the top pharmaceutical company and held about 24 percent of the global vaccine market by revenue. GSK is expected to maintain their position as the top company and even gain a small amount of the market until 2024. Pfizer is expected to account for some 16 percent of the global vaccine market by 2024, largely due to success with its pneumococcal vaccine, Prevnar 13. A vaccine often contains an agent that is made from a weakened form of a disease microbe, that is then used to stimulate the body's immune system to destroy and recognize the microorganism in case of later exposures.

Seqirus/CSL Behring is among the global leaders and has provided patient consumers new vaccines with these recent approvals: AUDENZ  the first and only adjuvanted, cell-based pandemic vaccine to provide active immunization against the influenza A virus H5N1 strain; FLUAD a seasonal vaccine in February 2020 in the US; and FLUCELVAX a seasonal vaccine for children and adults in Canada.

[READ MORE]

Global biotech leader CSL has formally offered to help governments around the world

(March 2020) -- To speed treatments, global biotech leader CSL is lend ingthe company’s expertise in science and manufacturing to address the recent coronavirus global pandemic.  The company is exploring development of a hyperimmune serum that could be derived from the blood plasma of people who have recovered from coronavirus. Once an adequate number of recovered patients is identified, it’s our hope that CSL could begin to collect their plasma and create a hyperimmune serum enriched with COV-19 antibodies to use as a therapy.

Though more research and testing is necessary, it’s believed that antibodies found in the plasma of now-healthy COVID-19 patients could potentially be used to boost the immune response of those who are struggling with the infection. By now it is well known that coronavirus causes mild flu-like symptoms in many, but others who are older than 60 or have additional medical conditions are at high risk of fatal complications.

[READ MORE]